W
WAVEMAN · COMPANY
AMLX · Amylyx Pharmaceuticals, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

AMLX

Amylyx Pharmaceuticals, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001658551
FORM 144 · 1☆ WATCH
INSIDER NET · 180D
-$487.5K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
121
13F, latest reported quarter
REVENUE GROWTH
-100.0%
XBRL, annual
NET MARGIN
-
CONVERSIONS · 180D
2
codes C/M, not in net · $170.2K priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$487.5K over 180 days
-$538.9K over 90 days
below 56% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
121 funds added or opened last quarter
more than 73% of Pharma & Biotech
REVENUE
-100.0% year over year
the lowest in Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
12.0% of shares outstanding short · 6.8 days to cover · settled 2026-07-31
more than 84% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
121 funds added or opened positions in the latest 13F quarter, of 209 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +241.7%
+241.7%12M
-1%+98%+198%+297%2025-092025-102025-122026-032026-052026-072026-09 2026-01-15 · Cohen Joshua B sold $1.9M2026-01-15 · Klee Justin B. sold $1.8M2025-09-30 · Klee Justin B. sold $427.9K2025-09-30 · Cohen Joshua B sold $426.4K2026-03-02 · Cohen Joshua B sold $424.0K2026-03-02 · Klee Justin B. sold $423.7K2026-07-09 · Mazzariello Gina sold $274.7K2026-07-10 · Mazzariello Gina sold $264.1K2026-02-02 · Klee Justin B. sold $227.7K2026-02-02 · Cohen Joshua B sold $227.5K2025-09-30 · Bedrosian Camille L sold $175.5K2025-09-30 · FRATES JAMES M sold $154.7K2025-09-30 · Mazzariello Gina sold $128.7K2026-03-02 · FRATES JAMES M sold $114.8K2025-12-23 · Firestone Karen bought $100.8K2026-03-02 · Mazzariello Gina sold $99.4K2025-12-01 · Bedrosian Camille L sold $94.4K2026-03-02 · Bedrosian Camille L sold $94.2K2026-01-06 · Cohen Joshua B sold $85.6K2026-01-06 · Klee Justin B. sold $85.6K2026-02-02 · FRATES JAMES M sold $52.1K2026-05-21 · Firestone Karen bought $51.3K2026-02-02 · Mazzariello Gina sold $50.5K2026-02-23 · Mazzariello Gina sold $48.3K2026-01-06 · FRATES JAMES M sold $37.0K2026-01-16 · Klee Justin B. sold $27.7K2026-01-16 · Cohen Joshua B sold $27.3K2025-09-30 · Klee Justin B. sold $3.0K2025-09-30 · Cohen Joshua B sold $3.0K2026-07-09 · GINA MAZZARIELLO filed to sell $536.4K
INSIDER BUYINSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $487.5K sold by insiders over 180 days, 121 funds added last quarter, $536.4K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Amylyx Pharmaceuticals, Inc. insiders sold a net $487.5K of stock across 143 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
Mazzariello Gina
Chief Legal Officer
SELL
2026-07-10
15,000.0
$264.1K
Mazzariello Gina
Chief Legal Officer
SELL
2026-07-09
15,000.0
$274.7K
Firestone Karen
Director
BUY
2026-05-21
3,800.0
$51.3K
Klee Justin B.
Co-Chief Executive Officer
SELL
2026-03-02
29,282.0
$423.7K
Cohen Joshua B
Co-Chief Executive Officer
SELL
2026-03-02
29,282.0
$424.0K
143 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 138 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
FMR LLC
16,727,909.0 sh
$300.4M
BlackRock, Inc.
8,827,085.0 sh
$158.5M
PERCEPTIVE ADVISORS LLC
8,334,882.0 sh
$149.7M
TCG Crossover Management, LLC
6,243,812.0 sh
$112.1M
Commodore Capital LP
5,650,000.0 sh
$101.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
GINA MAZZARIELLO
FILED 2026-07-09
$536.4K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Fidelity Advisor Biotechnology Fund
$38.9M POSITION · AS OF 2026-04-30
2.0%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.5M POSITION · AS OF 2026-03-31
1.8%
PROFUND VP PHARMACEUTICALS
$174.4K POSITION · AS OF 2026-03-31
1.7%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$184.9K POSITION · AS OF 2026-04-30
1.4%
Eventide Healthcare & Life Sciences Fund
$21.0M POSITION · AS OF 2026-03-31
1.3%
ALPS Medical Breakthroughs ETF
$1.5M POSITION · AS OF 2026-02-28
1.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 12 registered trials, 3 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
4
Phase 2
1 ACTIVE
3
Phase 3
1 ACTIVE
1
Not applicable
0 ACTIVE
3
Multi-phase
0 ACTIVE
What changed recently
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
2026-09-03 · Active Not Recruiting → Unknown
Phase 3
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$0$87.4M$380.8M$22.2M
OPERATING INCOME$-153.3M$-314.7M$38.8M$-201.3M
NET INCOME$-144.7M$-301.7M$49.3M$-198.4M
EPS (DILUTED)-1.53-4.430.70-3.39
OPERATING CASH FLOW$-123.3M$-167.6M$11.9M$-179.9M
CASH$226.7M$77.4M$170.2M$62.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →